New drug LP-184 tested on tough cancers: hope for Late-Stage patients

NCT ID NCT05933265

Ongoing Disease control Sponsor: Lantern Pharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an infusion twice per cycle.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic adenocarcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR DDR GENE MUTATION GBM METASTATIC SOLID TUMOR NSCLC PANCREATIC ADENOCARCINOMA TNBC - TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Locations

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Highlands Oncology Group

Springdale, Arkansas, 72758, United States
Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
John Hopkins - The Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21287, United States
Norton Healthcare, Inc.

Louisville, Kentucky, 40205, United States
START Mountain Region

West Valley City, Utah, 84119, United States
UT Health Science Center San Antonio

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.